BulbaMan,
Thanks for the SMDX update. Good only for 5% at the moment. Will have to look more closely at this pure play and competing products, if any. Help appreciated.
Speaking of pure plays, the Trickle Portfolio manager believes he has found a new overlooked pure play trickle company. I am so chuffed:
biz.yahoo.com
Apologies if someone has mentioned it and I forgot.
Here's an invite to Rick, tommysdad, and anyone else with field experience to check out their goods:
argotech.com
Haven't come to any valuation conclusions yet, much less setting of a buy target, but should dry powder be available in late winter, lock-up expiration could provide a fresh opportunity:
ipolockup.com
Pretty sizeable overhang, that.
Throwing it without a target into the watch list.
In the course of finding AGNT, I came across some other players in the space that haven't been discussed much here, if at all. However, few of these are pure trickle pays in the sense that the lions share of their business comes from sales to biotech labs. Many sell to hospital diagnostic labs and such. Others seem mainly to be clinical diagnostic companies. Some sell equipment to other kinds of chemists, outside the health care industry entirely. And some I'm just not sure. Please help biotoddler portfolio manager sort the following list in order of "trickleness" as we think we know it.
PLL
SPTM
VGIN
BEC
BIOa (Bio-Rad)
VAR
ILMN
CPHD
MSON
LMNX
XENO
I remember an article proclaiming the sequencing of the human genome as good news for humans, bad news for mice. So I'm also thinking of the mouse category, as it clearly qualifies as trickle. As I understand it, it comes in two basic flavors: 1) basic knock-out mice, and 2) transgenic mice designed to humanize antibodies. This is not to say that I know what I'm talking about here. Corrections invited. Example of flavor #1 would be CRL, and examples of flavor #2 would be ABGX, MEDX, LEXG, etc. Meanwhile, the mice are rooting for Xenogen, still privately held. Their continuous real time imaging technology allows in vivo studies of cellular reactions in mice for superior results in preclinical studies of PK & PD, ADME, etc. Without having to kill the mouse. This could be extended to other experimental animals, at least up to some size-limited (I would think) point. In unclogging a preclinical bottleneck, this would seem a compelling investment. The Trickle Portfolio awaits the opportunity to take a position in this company on general principle.
Check 'em out at: xenogen.com
Cheers, Tuck |
